Winning its second FDA approval this year, Boehringer Ingelheim's oral drug Jascayd is now cleared for use in the U.S. by ...

Columnist Samuel Kirton talks with the Pulmonary Fibrosis Foundation's Amy Hajari Case, MD, about the Accelerate Research ...

GRI-0621, an experimental oral therapy from GRI Bio, boosts lung function in adults with IPF, according to top-line clinical ...

Caring for someone you love is intimate, humbling, and grounding, writes columnist Ann Reynoso, who swapped caregiver roles with her husband.

Columnist Sam Kirton has wonderful memories of holiday presents, but the greatest gift he's received came in the form of a lung transplant.

Building on positive Phase 2 data, Puretech plans to launch a Phase 3 trial to further evaluate its experimental IPF therapy deupirfenidone.

[vc_row][vc_column][vc_column_text] Tipelukast (MN-001) is an oral macromolecular formulation developed originally by Kyorin Pharmaceuticals and now in clinical trials in the United States by ...

Musicians who play wind instruments are being warned of a potential hazard doctors have dubbed “bagpipe lung” — after a case study was published of a man who died of a lung condition known as ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF).

The U.S. Food and Drug Administration (FDA) recently granted orphan drug designation to Calluna Pharma‘s CAL101 as a potential treatment for idiopathic pulmonary fibrosis (IPF). This designation is ...